Enhanced Serum Levels of sFlt1: Impact on Materno–Fetal CMV Transmission
1
Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital of Tuebingen, Elfriede-Aulhorn-Straße 6, 72076 Tuebingen, Germany
2
Department of Obstetrics and Gynaecology, University Hospital of Tuebingen, Calwerstrasse 7, 72076 Tuebingen, Germany
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(5), 1258; https://doi.org/10.3390/jcm9051258
Received: 20 March 2020 / Revised: 18 April 2020 / Accepted: 23 April 2020 / Published: 26 April 2020
(This article belongs to the Section Obstetrics & Gynecology)
Background: Antenatal Cytomegalovirus infection (CMV) can be associated with severe fetal symptoms and newborn outcome. The current prenatal diagnosis is based on amniocentesis (AC). No reliable biomarker for fetal infection is available. Methods: We measured Placenta-derived growth factor (PlGF), and soluble fms-like tyrosine kinase 1 (sFlt1), concentrations in maternal serum and amniotic fluid (AF) in context of maternal CMV primary infection. Blood sampling was carried out at the time of AC for detection of fetal CMV infection. The study cohort was divided into four subcohorts according to the presence or absence of fetal infection and preemptive hyperimmunoglobulin (HIG) treatment during the time interval between diagnosis of the CMV primary infection and AC. Results: The study cohort involved 114 pregnancies. In the non-transmitting subcohorts (NT) with and without prior HIG treatment, the median sFlt1 concentrations were 1.5 ng/mL (NT, HIG+) and 1.4 ng/mL (NT, HIG−), respectively. In the two transmitting groups (T) the concentrations were 1.3 ng/mL (T, HIG+) and 2.3 ng/mL (T, HIG−), respectively (NT, HIG− vs. T, HIG−, p < 0.001). The corresponding PlGF levels and the sFlt1/PlGF ratios showed no significant differences between the cohorts. The empirical cut-off values <1504 pg/mL sFlt1 and <307 pg/mL PlGF, were associated with the exclusion of CMV transmission (p < 0.001). Conclusion: sFlt1 concentration in the maternal blood could be a predictive biomarker for maternofetal CMV transmission.
View Full-Text
Keywords:
CMV; pregnancy; soluble fms-like tyrosine kinase 1; sFlt1; placental growth factor; PlGF; hyperimmunoglobulin; HIG
▼
Show Figures
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
- Supplementary File 1:
PDF-Document (PDF, 365 KiB)
MDPI and ACS Style
Penka, L.; Kagan, K.-O.; Hamprecht, K. Enhanced Serum Levels of sFlt1: Impact on Materno–Fetal CMV Transmission. J. Clin. Med. 2020, 9, 1258. https://doi.org/10.3390/jcm9051258
AMA Style
Penka L, Kagan K-O, Hamprecht K. Enhanced Serum Levels of sFlt1: Impact on Materno–Fetal CMV Transmission. Journal of Clinical Medicine. 2020; 9(5):1258. https://doi.org/10.3390/jcm9051258
Chicago/Turabian StylePenka, Lukas; Kagan, Karl-Oliver; Hamprecht, Klaus. 2020. "Enhanced Serum Levels of sFlt1: Impact on Materno–Fetal CMV Transmission" J. Clin. Med. 9, no. 5: 1258. https://doi.org/10.3390/jcm9051258
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit